Clinical Trials Browser

INDUSTRY × dostarlimab × Gynecologic × Clear all

Ovarian Neoplasms

NCT07108270 2025-12-22

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)

Phase 2 Recruiting

30 enrolled

Gynecologic

Endometrial Neoplasms

NCT05277051 2025-12-19

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

158 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06317311 2025-07-25

RUBY-J

Phase 2 Active not recruiting

41 enrolled

Gynecologic

Carcinoma, Endometrial Neoplasms

NCT03574779 2025-07-15

OPAL

Phase 2 Completed

77 enrolled 8 charts

Gynecologic

Ovarian Neoplasms

NCT06897527 2025-07-08

A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)

Phase 4 Not yet recruiting

100 enrolled

Gynecologic

Endometrial Neoplasms

NCT05126342 2025-04-06

Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

Phase 2 Withdrawn

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05751629 2023-04-21

COHORT-A

Phase 2 Completed

41 enrolled 17 charts

Gynecologic

Ovarian Neoplasms

NCT03955471 2022-09-10

MOONSTONE

Phase 2 Terminated

41 enrolled 22 charts

Gynecologic

Ovarian Neoplasms

Clinical Trials

FIRST

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

RUBY-J

OPAL

A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)

Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

COHORT-A

MOONSTONE